Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 34, Issue 10, Pages 2635-2641Publisher
WILEY
DOI: 10.1002/eji.200425474
Keywords
transgenic tumor models; angiogenesis; immune therapy
Categories
Ask authors/readers for more resources
In immunological cancer therapy, the current treatment emphasis is on the generation of effector cells that are specific for tumor antigens. However, there is a distressing lack of correlation between the induction of specific immunity in cancer patients and measurable clinical benefit. By studying mouse models of de novo tumongenesis we are beginning to understand that the tumor itself, in particular the manifestation of a distinct tumor environment, impairs immune effector function; this concept is yet to be applied in human malignancy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available